MD

Business Context and Reporting Period

Company: Pediatrix Medical Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003
Business Overview: The Company operates as a physician group practice specializing in neonatal and perinatal care. The financial statements include the Company, its subsidiaries, and professional associations with which it has management arrangements.

Key Financial Metrics

Note: Working capital calculated as Total Current Assets ($108,919) minus Total Current Liabilities ($61,940). Q1 2002 working capital derived from comparative balance sheet data not fully detailed in text but referenced in MD&A as $79.6 million.

Material Changes vs. Prior Period

• Revenue Growth: Net patient service revenue increased 17.6% ($18.9 million). This was driven by a 14.2% increase in same-unit revenue (due to higher patient days, volume growth, and price increases) and 20.6% growth from new units acquired.
• Expense Increases: Practice salaries and benefits rose 19.3% ($12.1 million) due to new staff, incentive compensation, and higher insurance costs. General and administrative expenses increased 4.1% ($0.7 million), excluding a $1.3 million settlement cost present in the prior year.
• Profitability: Operating income grew 24.1% to $27.6 million. Net income increased 26.1% to $17.0 million. Operating margin improved by 1.1 percentage points to 21.8%.
• Cash Flow: Operating cash flow turned negative at $(6.5) million, compared to $4.6 million positive in the prior year. This was primarily due to the payment of accrued physician bonuses and 401(k) matching contributions from 2002, alongside payroll tax payments.
• Stock Repurchases: The Company utilized approximately $50 million of cash to repurchase 1.6 million shares of common stock during the quarter, significantly reducing cash reserves from $73.2 million to $13.6 million.

Guidance, Outlook, Risks, and Unusual Items

• Capital Resources: The Company maintains a $100 million line of credit with no outstanding balance as of March 31, 2003. Management anticipates sufficient funds to meet obligations for the next 12 months.
• Stock Repurchase Program: In April 2003, the Board authorized an additional $50 million for stock repurchases following the completion of the initial $50 million program.
• Legal Proceedings (FTC): The Federal Trade Commission is investigating competition issues related to the 2001 acquisition of Magella Healthcare Corporation. The Company received a subpoena in February 2003. The outcome is unpredictable and could have a material adverse effect.
• Legal Proceedings (TRICARE): An ongoing federal investigation into billing practices for the TRICARE program (military dependents) remains active.
• Accounting Changes: The Company is evaluating the impact of FASB Interpretation No. 46 (FIN 46) regarding the consolidation of two variable interest entities with approximately $16.0 million in assets and liabilities.
• Management Change: In March 2003, Kristen Bratberg resigned as CEO. Roger J. Medel, M.D., resumed the duties of CEO on a permanent basis.

Investor Verification Checklist

• Cash Position: Verify the sustainability of operations given the sharp decline in cash reserves ($73.2M to $13.6M) driven by stock buybacks and bonus payments.
• Regulatory Risk: Monitor the status of the FTC investigation regarding the Magella acquisition and the ongoing TRICARE billing audit for potential fines or operational restrictions.
• Debt Covenants: Confirm continued compliance with the $100 million line of credit covenants, specifically regarding minimum net worth and earnings, despite the recent cash outflows.
• Stock-Based Compensation: Review pro forma net income ($14.5 million) which is lower than reported net income ($17.0 million) if fair value accounting for stock options were applied.
• Acquisition Integration: Assess the performance of the one physician group acquired in Q1 2003 ($2.6 million consideration) to ensure it meets revenue projections.